| 20.74 -0.54 (-2.54%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 26.77 |
1-year : | 28.46 |
| Resists | First : | 22.92 |
Second : | 24.37 |
| Pivot price | 22.58 |
|||
| Supports | First : | 20.58 |
Second : | 17.12 |
| MAs | MA(5) : | 21.53 |
MA(20) : | 22.55 |
| MA(100) : | 21.29  |
MA(250) : | 19.44 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 4 |
D(3) : | 8.6 |
| RSI | RSI(14): 37.3 |
|||
| 52-week | High : | 25.34 | Low : | 11.21 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ SNDX ] has closed below the lower bollinger band by 0.3%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 8.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 21.58 - 21.73 | 21.73 - 21.85 |
| Low: | 20.2 - 20.4 | 20.4 - 20.55 |
| Close: | 20.46 - 20.73 | 20.73 - 20.94 |
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
Tue, 09 Apr 2024
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Acquired by Vanguard Group Inc. - Defense World
Thu, 04 Apr 2024
SG Americas Securities LLC Increases Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Fri, 29 Mar 2024
Analysts Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) PT at $34.42 - MarketBeat
Thu, 28 Mar 2024
Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope (NASDAQ:SNDX) - Seeking Alpha
Thu, 28 Mar 2024
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA - Yahoo Finance
Mon, 18 Mar 2024
Syndax Pharmaceuticals Welcomes New CCO Steven Closter - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 85 (M) |
| Shares Float | 85 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 106.6 (%) |
| Shares Short | 9,620 (K) |
| Shares Short P.Month | 9,090 (K) |
| EPS | -2.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.53 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.9 % |
| Return on Equity (ttm) | -41 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.71 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -161 (M) |
| Levered Free Cash Flow | -82 (M) |
| PE Ratio | -6.96 |
| PEG Ratio | 0 |
| Price to Book value | 3.17 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|